{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T16:04:51Z","timestamp":1761581091658},"reference-count":43,"publisher":"Oxford University Press (OUP)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2013,8,15]]},"DOI":"10.1093\/infdis\/jit223","type":"journal-article","created":{"date-parts":[[2013,5,18]],"date-time":"2013-05-18T05:30:40Z","timestamp":1368855040000},"page":"662-671","source":"Crossref","is-referenced-by-count":19,"title":["Clinical and Genetic Determinants of Plasma Nevirapine Exposure Following an Intrapartum Dose to Prevent Mother-to-Child HIV Transmission"],"prefix":"10.1093","volume":"208","author":[{"given":"Saran","family":"Vardhanabhuti","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edward P.","family":"Acosta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heather J.","family":"Ribaudo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrice","family":"Severe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Umesh","family":"Lalloo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nagalingeshwaran","family":"Kumarasamy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frank","family":"Taulo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph","family":"Kabanda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olola","family":"Oneko","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Prudence","family":"Ive","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pradeep","family":"Sambarey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ellen S.","family":"Chan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jane","family":"Hitti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francis","family":"Hong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deborah","family":"McMahon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David W.","family":"Haas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2013,5,17]]},"reference":[{"key":"key\n\t\t\t\t20170511123747_JIT223C1","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/S0140-6736(99)07419-X","article-title":"Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIVNET 012 randomised trial","volume":"354","author":"Guay","year":"1999","journal-title":"Lancet"},{"key":"key\n\t\t\t\t20170511123747_JIT223C2","doi-asserted-by":"crossref","first-page":"F111","DOI":"10.1097\/00002030-200007280-00001","article-title":"Identification of the K103N resistance mutation in Ugandan women receiving nevirapine to prevent HIV-1 vertical transmission","volume":"14","author":"Jackson","year":"2000","journal-title":"AIDS"},{"key":"key\n\t\t\t\t20170511123747_JIT223C3","first-page":"483","article-title":"Kinetics of nevirapine and its impact on HIV-1 RNA levels in maternal plasma and breast milk over time after perinatal single dose nevirapine","volume":"60","author":"Aizire","year":"2012","journal-title":"JAIDS"},{"key":"key\n\t\t\t\t20170511123747_JIT223C4","doi-asserted-by":"crossref","first-page":"e1000172","DOI":"10.1371\/journal.pmed.1000172","article-title":"Efficacy of short-course AZT plus 3TC to reduce nevirapine resistance in the prevention of mother-to-child HIV transmission: a randomized clinical trial","volume":"6","author":"McIntyre","year":"2009","journal-title":"PLoS Med"},{"key":"key\n\t\t\t\t20170511123747_JIT223C5","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1089\/aid.2009.0088","article-title":"Intrapartum tenofovir and emtricitabine reduces low-concentration drug resistance selected by single-dose nevirapine for perinatal HIV prevention","volume":"25","author":"Chi","year":"2009","journal-title":"AIDS Res Hum Retroviruses"},{"key":"key\n\t\t\t\t20170511123747_JIT223C6","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1097\/QAD.0b013e32832949d5","article-title":"Tolerance and viral resistance after single-dose nevirapine with tenofovir and emtricitabine to prevent vertical transmission of HIV-1","volume":"23","author":"Arrive","year":"2009","journal-title":"AIDS"},{"key":"key\n\t\t\t\t20170511123747_JIT223C7","doi-asserted-by":"crossref","first-page":"1698","DOI":"10.1016\/S0140-6736(07)61605-5","article-title":"Single-dose tenofovir and emtricitabine for reduction of viral resistance to non-nucleoside reverse transcriptase inhibitor drugs in women given intrapartum nevirapine for perinatal HIV prevention: an open-label randomised trial","volume":"370","author":"Chi","year":"2007","journal-title":"Lancet"},{"key":"key\n\t\t\t\t20170511123747_JIT223C8","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1086\/650745","article-title":"Efficacy and safety of 1-month postpartum zidovudine-didanosine to prevent HIV-resistance mutations after intrapartum single-dose nevirapine","volume":"50","author":"Lallemant","year":"2010","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20170511123747_JIT223C9","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1093\/jac\/dkn441","article-title":"Persistence of nevirapine in breast milk and plasma of mothers and their children after single-dose administration","volume":"63","author":"Kunz","year":"2009","journal-title":"J Antimicrob Chemother"},{"key":"key\n\t\t\t\t20170511123747_JIT223C10","first-page":"419","article-title":"Nevirapine plasma concentrations are still detectable after more than 2 weeks in the majority of women receiving single-dose nevirapine: implications for intervention studies","volume":"39","author":"Muro","year":"2005","journal-title":"JAIDS"},{"key":"key\n\t\t\t\t20170511123747_JIT223C11","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1097\/00006454-200108000-00017","article-title":"Nevirapine pharmacokinetics in pregnant women and in their infants after in utero exposure","volume":"20","author":"Mirochnick","year":"2001","journal-title":"Pediat Infect Dis J"},{"key":"key\n\t\t\t\t20170511123747_JIT223C12","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1086\/597125","article-title":"Associations between CYP2B6 polymorphisms and pharmacokinetics after a single dose of nevirapine or efavirenz in African Americans","volume":"199","author":"Haas","year":"2009","journal-title":"J Infect Dis"},{"key":"key\n\t\t\t\t20170511123747_JIT223C13","first-page":"1488","article-title":"Characterization of the in vitro biotransformation of the HIV-1 reverse transcriptase inhibitor nevirapine by human hepatic cytochromes P-450","volume":"27","author":"Erickson","year":"1999","journal-title":"Drug Metab Dispos"},{"key":"key\n\t\t\t\t20170511123747_JIT223C14","doi-asserted-by":"crossref","first-page":"598","DOI":"10.2174\/138920008785821710","article-title":"CYP2B6: new insights into a historically overlooked cytochrome P450 isozyme","volume":"9","author":"Wang","year":"2008","journal-title":"Current Drug Metab"},{"key":"key\n\t\t\t\t20170511123747_JIT223C15","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1124\/dmd.108.024851","article-title":"Metabolic activation of nevirapine in human liver microsomes: dehydrogenation and inactivation of cytochrome P450 3A4","volume":"37","author":"Wen","year":"2009","journal-title":"Drug Metab Dispos"},{"key":"key\n\t\t\t\t20170511123747_JIT223C16","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.clpt.2005.04.004","article-title":"Intracellular and plasma pharmacokinetics of nevirapine in human immunodeficiency virus-infected individuals","volume":"78","author":"Almond","year":"2005","journal-title":"Clin Pharm Therap"},{"key":"key\n\t\t\t\t20170511123747_JIT223C17","first-page":"895","article-title":"Disposition and biotransformation of the antiretroviral drug nevirapine in humans","volume":"27","author":"Riska","year":"1999","journal-title":"Drug Metab Dispos"},{"key":"key\n\t\t\t\t20170511123747_JIT223C18","doi-asserted-by":"crossref","first-page":"276","DOI":"10.2133\/dmpk.22.276","article-title":"Broad but distinct role of pregnane x receptor on the expression of individual cytochrome p450s in human hepatocytes","volume":"22","author":"Kojima","year":"2007","journal-title":"Drug Metab Pharmacokinet"},{"key":"key\n\t\t\t\t20170511123747_JIT223C19","first-page":"2391","article-title":"Pharmacogenetics of efavirenz and central nervous system side effects: an Adult AIDS Clinical Trials Group study","volume":"18","author":"Haas","year":"2004","journal-title":"AIDS"},{"key":"key\n\t\t\t\t20170511123747_JIT223C20","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1124\/jpet.103.049601","article-title":"The cytochrome P450 2B6 (CYP2B6) is the main catalyst of efavirenz primary and secondary metabolism: implication for HIV\/AIDS therapy and utility of efavirenz as a substrate marker of CYP2B6 catalytic activity","volume":"306","author":"Ward","year":"2003","journal-title":"J Pharm Exp Therap"},{"key":"key\n\t\t\t\t20170511123747_JIT223C21","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/01213011-200501000-00001","article-title":"Influence of CYP2B6 polymorphism on plasma and intracellular concentrations and toxicity of efavirenz and nevirapine in HIV-infected patients","volume":"15","author":"Rotger","year":"2005","journal-title":"Pharmacogenet Genom"},{"key":"key\n\t\t\t\t20170511123747_JIT223C22","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1093\/jac\/dkn029","article-title":"Impact of CYP2B6 983T\u2192C polymorphism on non-nucleoside reverse transcriptase inhibitor plasma concentrations in HIV-infected patients","volume":"61","author":"Wyen","year":"2008","journal-title":"J Antimicrob Chemother"},{"key":"key\n\t\t\t\t20170511123747_JIT223C23","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1111\/j.1468-1293.2008.00689.x","article-title":"Cytochrome P450 2B6 516G\u2192T is associated with plasma concentrations of nevirapine at both 200 mg twice daily and 400 mg once daily in an ethnically diverse population","volume":"10","author":"Mahungu","year":"2009","journal-title":"HIV Med"},{"key":"key\n\t\t\t\t20170511123747_JIT223C24","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1111\/j.1468-1293.2007.00432.x","article-title":"Cytochrome P450 2B6 (CYP2B6) G516T influences nevirapine plasma concentrations in HIV-infected patients in Uganda","volume":"8","author":"Penzak","year":"2007","journal-title":"HIV Med"},{"key":"key\n\t\t\t\t20170511123747_JIT223C25","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1097\/QAD.0b013e3282ef9695","article-title":"CYP2B6 genetic variants are associated with nevirapine pharmacokinetics and clinical response in HIV-1-infected children","volume":"21","author":"Saitoh","year":"2007","journal-title":"AIDS"},{"key":"key\n\t\t\t\t20170511123747_JIT223C26","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1093\/jac\/dkp033","article-title":"Association of high T allele frequency of CYP2B6 G516T polymorphism among ethnic south Indian HIV-infected patients with elevated plasma efavirenz and nevirapine","volume":"63","author":"Ramachandran","year":"2009","journal-title":"J Antimicrob Chemother"},{"key":"key\n\t\t\t\t20170511123747_JIT223C27","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/1742-6405-7-8","article-title":"Effects of CYP2B6 G516T polymorphisms on plasma efavirenz and nevirapine levels when co-administered with rifampicin in HIV\/TB co-infected Thai adults","volume":"7","author":"Uttayamakul","year":"2010","journal-title":"AIDS Res Ther"},{"key":"key\n\t\t\t\t20170511123747_JIT223C28","doi-asserted-by":"crossref","first-page":"4432","DOI":"10.1128\/AAC.00512-10","article-title":"Population pharmacokinetic-pharmacogenetic study of nevirapine in HIV-infected Cambodian patients","volume":"54","author":"Chou","year":"2010","journal-title":"Antimicrob Ag Chemother"},{"key":"key\n\t\t\t\t20170511123747_JIT223C29","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1093\/jac\/dkp351","article-title":"Influence of CYP2B6 polymorphisms on the persistence of plasma nevirapine concentrations following a single intra-partum dose for the prevention of mother to child transmission in HIV-infected Thai women","volume":"64","author":"Chantarangsu","year":"2009","journal-title":"J Antimicrob Chemother"},{"key":"key\n\t\t\t\t20170511123747_JIT223C30","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1097\/01.fpc.0000189797.03845.90","article-title":"Identification of a novel specific CYP2B6 allele in Africans causing impaired metabolism of the HIV drug efavirenz","volume":"16","author":"Wang","year":"2006","journal-title":"Pharmacogenet Genom"},{"key":"key\n\t\t\t\t20170511123747_JIT223C31","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1086\/655470","article-title":"Effect of CYP2B6, ABCB1, and CYP3A5 polymorphisms on efavirenz pharmacokinetics and treatment response: an AIDS Clinical Trials Group study","volume":"202","author":"Ribaudo","year":"2010","journal-title":"J Infect Dis"},{"key":"key\n\t\t\t\t20170511123747_JIT223C32","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1097\/FPC.0b013e32835a5af2","article-title":"Multiple genetic variants predict steady-state nevirapine clearance in HIV-infected Cambodians","volume":"22","author":"Bertrand","year":"2012","journal-title":"Pharmacogenet Genom"},{"key":"key\n\t\t\t\t20170511123747_JIT223C33","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1097\/FPC.0b013e32835a450b","article-title":"Genome-wide association study of plasma efavirenz pharmacokinetics in AIDS Clinical Trials Group protocols","volume":"22","author":"Holzinger","year":"2012","journal-title":"Pharmacogenet Genom"},{"key":"key\n\t\t\t\t20170511123747_JIT223C34","volume-title":"dbSNP - short genetic variations"},{"key":"key\n\t\t\t\t20170511123747_JIT223C35","doi-asserted-by":"crossref","first-page":"5938","DOI":"10.1128\/AAC.00691-12","article-title":"Novel method to assess antiretroviral target trough concentrations using in vitro susceptibility data","volume":"56","author":"Acosta","year":"2012","journal-title":"Antimicrob Ag Chemother"},{"key":"key\n\t\t\t\t20170511123747_JIT223C36","doi-asserted-by":"crossref","first-page":"9202","DOI":"10.1073\/pnas.1105688108","article-title":"Role of low-frequency HIV-1 variants in failure of nevirapine-containing antiviral therapy in women previously exposed to single-dose nevirapine","volume":"108","author":"Boltz","year":"2011","journal-title":"Proc Natl Acad Sci U S A"},{"key":"key\n\t\t\t\t20170511123747_JIT223C37","author":"SeattleSNPs variation discovery resource"},{"key":"key\n\t\t\t\t20170511123747_JIT223C38","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1038\/sj.clpt.6100072","article-title":"Predictive value of known and novel alleles of CYP2B6 for efavirenz plasma concentrations in HIV-infected individuals","volume":"81","author":"Rotger","year":"2007","journal-title":"Clin Pharmacol Therap"},{"key":"key\n\t\t\t\t20170511123747_JIT223C39","author":"Ensembl"},{"key":"key\n\t\t\t\t20170511123747_JIT223C40","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1124\/jpet.103.054866","article-title":"Hepatic CYP2B6 Expression: Gender and Ethnic Differences and Relationship to CYP2B6 Genotype and CAR Expression","volume":"307","author":"Lamba","year":"2003","journal-title":"J Pharmacol Exp Therap"},{"key":"key\n\t\t\t\t20170511123747_JIT223C41","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/S1473-3099(10)70288-7","article-title":"Triple antiretroviral compared with zidovudine and single-dose nevirapine prophylaxis during pregnancy and breastfeeding for prevention of mother-to-child transmission of HIV-1 (Kesho Bora study): a randomised controlled trial","volume":"11","author":"de Vincenzi","year":"2011","journal-title":"Lancet Infect Dis"},{"key":"key\n\t\t\t\t20170511123747_JIT223C42","first-page":"522","article-title":"Lower risk of resistance after short-course HAART compared with zidovudine\/single-dose nevirapine used for prevention of HIV-1 mother-to-child transmission","volume":"51","author":"Lehman","year":"2009","journal-title":"JAIDS"},{"key":"key\n\t\t\t\t20170511123747_JIT223C43","volume-title":"Antiretroviral drugs for treating pregnant women and preventing HIV infection in infants: recommendations for a public health approach, 2010 version","author":"HIV\/AIDS Programme, World Health Organization (WHO)","year":"2010"}],"container-title":["The Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jid\/article-pdf\/208\/4\/662\/16865902\/jit223.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,17]],"date-time":"2022-02-17T10:36:49Z","timestamp":1645094209000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jid\/article-lookup\/doi\/10.1093\/infdis\/jit223"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,5,17]]},"references-count":43,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2013,5,17]]},"published-print":{"date-parts":[[2013,8,15]]}},"URL":"https:\/\/doi.org\/10.1093\/infdis\/jit223","relation":{},"ISSN":["1537-6613","0022-1899"],"issn-type":[{"value":"1537-6613","type":"electronic"},{"value":"0022-1899","type":"print"}],"subject":[],"published":{"date-parts":[[2013,5,17]]}}}